The First-in-human Phase I Trial of PU-H71 in Patients With Advanced Malignancies
Status:
Active, not recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
NOTE: This study is now recruiting only patients with Myeloproliferative Neoplasms (MPN).
Dose escalation has been completed.
The purpose of this study is to test a new drug, called PU-H71 for the first time in humans,
to find out what effects, good or bad, this new drug has on the patient and the cancer at
different dose levels. PU-H71 blocks a protein called Heat Shock Protein-90 (Hsp90). Hsp90 is
found in both normal and cancer cells, but may be more important in cancer cells. Attacking
Hsp90 can stop the function of certain proteins that are needed for cancer cells to survive.
The diseases that are part of this study may be especially sensitive to attacking Hsp90, and
the investigators have seen signs of disease control in patients with MPN. This study is
currently enrolling a cohort expansion for patients with myeloproliferative neoplasms (MPN).